Related Experiment Videos

Long-term impact of secondary preventive treatments in patients with stable angina

Zoltán Vokó1, Sophie de Brouwer, Jacobus Lubsen

  • 1Department of Health Policy & Health Economics, Institute of Economics, Eötvös Loránd University, Budapest, Hungary. voko@caesar.elte.hu

European Journal of Epidemiology
|February 22, 2011
PubMed

Insights

This study found that certain medications, including ACE inhibitors/ARBs, lipid-lowering, and anti-platelet drugs, significantly reduce mortality in stable angina patients. Revascularization procedures like PCI and CABG also showed benefits.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Stable angina pectoris management involves various pharmacological and interventional strategies.
  • Understanding the independent effects of these treatments on long-term outcomes is crucial for optimizing patient care.
  • The ACTION trial provided a large cohort for evaluating secondary prevention in stable angina.

Purpose of the Study:

  • To assess the independent effects of multiple cardiovascular interventions on mortality and a composite endpoint in patients with stable angina.
  • To evaluate the secondary preventive effects of commonly used medications and procedures in routine clinical practice.

Main Methods:

  • Multivariate Cox regression and G-estimation were used to analyze data from 7,665 patients in the ACTION trial.
  • Patients were followed for a mean of 5 years, comparing users of specific treatments to non-users.
  • Outcomes assessed included all-cause mortality and a composite endpoint of death, myocardial infarction, stroke, or heart failure.

Main Results:

  • Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) showed a significant reduction in mortality (HR 0.82).
  • Lipid-lowering drugs (HR 0.54) and anti-platelet drugs (HR 0.49) demonstrated substantial independent protective effects on mortality.
  • Percutaneous coronary intervention (PCI) (HR 0.74) also significantly reduced mortality, while calcium antagonists and coronary artery bypass grafting (CABG) showed a trend towards benefit.

Conclusions:

  • ACEIs or ARBs, lipid-lowering drugs, and anti-platelet drugs provide independent secondary preventive benefits in the management of stable angina.
  • Calcium antagonists, PCI, and CABG also appear to improve outcomes in this patient population.
  • These findings reinforce the importance of guideline-directed medical therapy and revascularization in stable angina.

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...